Sens.ai
Graylight ImagingProduct specifications |
Information source:
Vendor
Last updated: Jan. 26, 2022 |
General | |
---|---|
Product name | Sens.ai |
Company | Graylight Imaging |
Subspeciality | Neuro |
Modality | MR |
Disease targeted | Low and high grade glioblastoma |
Key-features | Lesion segmentation and volume calculation |
Suggested use | |
Data characteristics | |
Population | all adults with glioblastoma |
Input | FLAIR 3D MR sequence |
Input format | DICOM |
Output | lesion segmentation, volume calculation |
Output format | DICOM |
Technology | |
Integration | Integration via AI marketplace or distribution platform, Stand-alone third party application |
Deployment | Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based |
Trigger for analysis | On demand, triggered by a user through e.g. a button click, image upload, etc. |
Processing time | 3 - 10 seconds |
Certification | |
CE
|
Certified,
Class IIa
, MDD
|
FDA
|
No or not yet |
Market presence | |
On market since | 03-2020 |
Distribution channels | Eureka Clinical AI |
Countries present (clinical, non-research use) | |
Paying clinical customers (institutes) | |
Research/test users (institutes) | |
Pricing | |
Pricing model | |
Based on | |
Evidence | |
Peer reviewed papers on performance |
|
Non-peer reviewed papers on performance | |
Other relevant papers |